03
2022-04
Kintor Pharma Announces Two Upcoming Poster Presentations at AACR 2022
Suzhou, April 3, 2022 - Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, including proxalutamide to treat COVID-19 and a c-Myc Degrader to treat blood cancer and small cell lung cancers (SCLC). This year’s AACR annual meeting will be held in the city of New Orleans, United States, on April 8-13, 2022.
25
2022-03
Kintor Pharma Announces 2021 Business Progress and Annual Results
Suzhou, March 25, 2022 - Kintor Pharmaceutical Limited (Kintor Pharma, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced business highlights and financial results for the year ended December 31, 2021.
06
2022-03
Suzhou, March 6, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment of 160 patients for its phase II clinical trial of KX-826 ("pyrilutamide") in China for the treatment of female androgenetic alopecia (AGA) on 4 March 2022, which has only taken around four months since its launch.
01
2022-03
Suzhou, March 1, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826 ("pyrilutamide") in the US for the treatment of male androgenetic alopecia (AGA) patients on February 28, 2022.
11
2022-02
Suzhou, February 11, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the enrollment and dosing of first patient in its multi-regional phase III clinical trial (NCT04869228) of proxalutamide for the treatment of COVID-19 outpatients in the Third People's Hospital of Shenzhen（深圳市第三人民医院）in China on 10 February 2022.
03
2022-02
Suzhou, February 3, 2022 - Kintor Pharmaceutical Limited (“Kintor Pharma,” HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the dosing of first subject in its U.S. phase I clinical trial of GT20029 (gel) for the treatment of androgenetic alopecia (AGA) and acne on 1 February 2022, US local time. Developed through Kintor’s proprietary Proteolysis Targeting Chimera (PROTAC) platform, GT20029 is the first topical PROTAC compound globally to enter the clinical stage.
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn